QuantX Biosciences

QuantX Biosciences

Private
Princeton, New JerseyHealthcare & Life Scienceshttps://quantxbio.com/

Last Round

Series B

Feb 9, 2026

Total Funding Raised

$130M

Momentum Score

50 /100

Company Overview

QuantX Biosciences is a biotechnology company that operates a computationally driven drug discovery platform to design and optimize oral small molecule therapeutics for immune-mediated and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Infrastructure

Keywords

computational drug discoveryAI drug discoverysmall molecule drugsdrug discovery platformphysics-based modelingtechbioin silico drug designimmunology therapeuticsinflammatory diseasesdrug pipeline developmentoral therapeuticshigh-performance computingSTAT6 inhibitorIL-17 inhibitordifficult-to-drug targets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

QuantX Biosciences Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

QuantX Biosciences Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 9, 2026

Key People

Founding team and executive leadership

Yax Sun

Co-founder And Chief Technology Officer

Founding Team

QuantX Biosciences Investors

Notable investors and investment history

InvestorRounds
Creacion VenturesSeries A, Series B
OrbiMedSeries A, Series B
HongShanSeries B
Sanofi VenturesSeries B
Lilly Asia VenturesSeries B
HongShanSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Grew 27% QoQ, from 22 to 28 employees.

  • Feb 9, 2026

    $85M Series B round completed.

QuantX Biosciences Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

QuantX Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about QuantX Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersPrinceton, New Jersey
Employee Range28
Year Founded2022
Last FundingFeb 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.